Trials / Unknown
UnknownNCT04332094
Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)
Pilot, Randomized, Multicenter, Open-label Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 276 (estimated)
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
COVID-19 is a respiratory disease caused by the new coronavirus (SARS-CoV-2) and causes considerable morbidity and mortality. Currently, there is no vaccine or therapeutic agent to prevent and treat a SARS-CoV-2 infection. This clinical trial is designed to evaluate the use of Tocilizumab in combination with hydroxychloroquine and azithromycin for the treatment of hospitalized adult patients with COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tocilizumab | 162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1) |
| DRUG | Hydroxychloroquine | 400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total) |
| DRUG | Azithromycin | 500 mg / day v.o. for 3 days |
Timeline
- Start date
- 2020-04-02
- Primary completion
- 2021-06-01
- Completion
- 2021-07-01
- First posted
- 2020-04-02
- Last updated
- 2021-05-06
Locations
7 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04332094. Inclusion in this directory is not an endorsement.